Metabolism studies of diclofenac and clofibric acid in activated sludge bioreactors using liquid chromatography with quadrupole – time-of-flight mass spectrometry

SummaryTwo environmentally relevant pharmaceuticals, the non-steroidal antiinflammatory drug, diclofenac and the pharmacologically active metabolite of several serum triglyceride-lowering pharmaceuticals, clofibric acid, were subjected to microbiological transformation in activated sludge bioreactors, and the production of breakdown products was studied. For separation, detection and identification of diclofenac’s metabolites a UPLC-(+)ESI-QqToF-MS was employed, which enabled the detection of seven transformation products of diclofenac, all including the diagnostic fragment ion at m/z 214. The chemical structure of one metabolite was proposed, which was produced by dehydratation and lactame formation. Further investigations revealed additional two metabolites, which were isomeric structures with an elemental composition C13H10NCl2; however, their chemical structures were not completely resolved. In addition, another biodegradation product showed an abundant fragment ion at m/z 295, the elemental composition of which was confirmed with a high degree of certainty as C14H11NO2Cl2. The biodegradation of clofibric acid revealed one metabolite in the (-)ESI-QqToF chromatogram, 4-chlorophenol, which is known to exhibit a higher toxicity than the parent compound. This study confirms that further research is needed on the formation of stable metabolites both during wastewater treatment and in the environment. It also highlights the need for parallel toxicity testing. In addition, this study suggests that more needs to be known about the environmental fate of pharmaceuticals so that we are able to provide a comprehensive risk assessment.